Skip to main content
NCBI home page
Archives of Disease in Childhood. Fetal and Neonatal Edition logoLink to Archives of Disease in Childhood. Fetal and Neonatal Edition
. 1997 May;76(3):F190–F192. doi: 10.1136/fn.76.3.f190

Randomised controlled double blind study of role of recombinant erythropoietin in the prevention of chronic lung disease

G Griffiths, R Lall, S Chatfield, A Short, P Mackay, P Williamson, J Brown, M Levene
PMCID: PMC1720643  PMID: 9175950

Abstract

AIM—To evaluate the role of recombinant human erythropoietin (R-HuEpo) in reducing iron infusion, which may exacerbate free radical damage, leading to chronic lung disease.
METHODS—A multicentre, randomised, placebo controlled, double blind study was carried out in four neonatal intensive care units in Yorkshire. Infants were randomly allocated and received either R-HuEpo (480 U/kg/wk) or placebo by twice weekly subcutaneous injection. The primary outcome measure was the number of days on respiratory support and a secondary outcome the number of blood transfusions required.
RESULTS—Forty two very low birthweight (VLBW) infants were randomly allocated. There was little difference in the need for respiratory support one month after randomisation, but subsequently there was a trend towards a reduction in the proportion requiring respiratory support in the R-HuEpo group (difference at three months −0.50, 95% confidence interval −1.00, 0.17). During stay in hospital, the median number of blood transfusions was lower for infants in the R-HuEpo group (difference in medians −2, 95% CI −4, 0). The study was stopped early because of failure to recruit babies at the expected rate.
CONCLUSIONS—R-HuEpo seems to reduce the number of days in oxygen for ill VLBW infants. These data could be used to construct a larger multicentre study to evaluate this effect further.

 Keywords: human erythropoietin; respiratory support; blood transfusions; chronic lung disease

Full Text

The Full Text of this article is available as a PDF (101.8 KB).

Figure 1  .

Figure 1  

Open in a new tab

Kaplan-Meier curves showing the probabilities of receiving ventilatory support and/or supplemental oxygen.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bany-Mohammed F. M., Slivka S., Hallman M. Recombinant human erythropoietin: possible role as an antioxidant in premature rabbits. Pediatr Res. 1996 Sep;40(3):381–387. doi: 10.1203/00006450-199609000-00003. [DOI] [PubMed] [Google Scholar]
  2. Ohls R. K., Hunter D. D., Christensen R. D. A randomized, double-blind, placebo-controlled trial of recombinant erythropoietin in treatment of the anemia of bronchopulmonary dysplasia. J Pediatr. 1993 Dec;123(6):996–1000. doi: 10.1016/s0022-3476(05)80401-9. [DOI] [PubMed] [Google Scholar]
  3. Peto R., Pike M. C., Armitage P., Breslow N. E., Cox D. R., Howard S. V., Mantel N., McPherson K., Peto J., Smith P. G. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. Br J Cancer. 1977 Jan;35(1):1–39. doi: 10.1038/bjc.1977.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Shannon K. Recombinant erythropoietin in anemia of prematurity: five years later. Pediatrics. 1993 Oct;92(4):614–617. [PubMed] [Google Scholar]
  5. Sullivan J. L. Iron, plasma antioxidants, and the 'oxygen radical disease of prematurity'. Am J Dis Child. 1988 Dec;142(12):1341–1344. doi: 10.1001/archpedi.1988.02150120095048. [DOI] [PubMed] [Google Scholar]
  6. Williamson P., Griffiths G., Norfolk D., Levene M. Blood transfusions and human recombinant erythropoietin in premature newborn infants. Arch Dis Child Fetal Neonatal Ed. 1996 Jul;75(1):F65–F68. doi: 10.1136/fn.75.1.f65. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Archives of Disease in Childhood Fetal and Neonatal Edition are provided here courtesy of BMJ Publishing Group

RESOURCES